Everand Logo

Welcome to Everand!

  • STAT

    FDA approves a new vaccine for shingles that provides broad protection

    In trials, the vaccine offered 98 percent protection in the first year and that protection remained at 85 percent or higher three years after vaccination.
    by Helen Branswell Oct 20, 2017 3 minutes

    The Food and Drug Administration on Friday approved a second shingles vaccine, giving pharmaceutical giant GlaxoSmithKline a go-ahead to market Shingrix in the United States.

    The FDA approval marks the second regulatory green light for the vaccine in a week’s time. Last Friday Shingrix was approved for sale in Canada. Regulatory filings are also in the works for the European Union, Australia, and Japan, GSK said.

    The vaccine offered 98 percent protection in the first year and that protection remained at 85 percent or higher three years after vaccination

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks